casno. : CAS 1950-2-2
Dexamethasone is an adrenocorticosteroid, mainly used in the treatment of dry allergic and immune inflammatory diseases, it has a good anti-inflammatory, anti-allergic and immunosuppressive effect, this product can reduce and prevent the tissue response to inflammation, thus reducing the manifestation of inflammation. The hormone inhibits the accumulation of inflammatory cells, including macrophages and leukocytes, at the site of inflammation and inhibits phagocytosis, the release of lysosomal enzymes, and the synthesis and release of inflammatory chemicals, mediators, which can attenuate and prevent the tissue response to inflammation and thus reduce the manifestation of inflammation.
Dexamethasone has excellent immunosuppressive effects, including prevention and suppression of delayed allergic reactions to cell-mediated immune responses, reduction in the number of T lymphocytes, monocytes, and eosinophils, reduction in the binding capacity of immunoglobulins to cell surface receptors, and inhibition of interleukin synthesis and release, thereby reducing the conversion of T lymphocytes to lymphoblasts.
It reduces the expansion of the primary immune response, reduces the passage of immune complexes through the basement membrane, and reduces the concentration of complement components and immunoglobulins.
Dexamethasone has a wide range of applications, strong effects and obvious curative effects. It is a commonly used glucocorticoid and plays a key role in rescuing acute and severe diseases such as allergic diseases, shock, endocrine crisis, etc. It is an indispensable drug in clinical practice. Dexamethasone has stronger anti-inflammatory effect and skin allergy control effect than prednisone. Its anti-inflammatory activity of 0.75 mg is equivalent to that of 5 mg prednisone, and it has better effect on skin allergy. For critical diseases such as persistent asthma, a large dose of dexamethasone can be given intravenously in a short period of time with a good effect. It can be given intravenously at 5~20mg each time, repeated at 4~6h, reduced at 48~72h, and stopped at 5~7 days. Patients with brain edema caused by various reasons can be given 10mg intravenous injection for the first time. After that, 2~4mg was injected intramuscularly every 4~6 hours, which was generally relieved within 24 hours, reduced within 48~72 hours, and stopped within 7 days.